Trial intelligence / Profile preview

Phase 2 study of futibatinib 20 mg versus 16 mg in advanced cholangiocarcinoma with FGFR2 fusion or rearrangement

CTR20251081Phase 2Active

Sponsor

Taiho Oncology

Start

Oct 2023

Modality

Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules

Countries

1